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Cognitive behavioural therapy (CBT) for psychosis (CBTp) aims to lower the stress of psychotic symptoms. Given
that the pituitary is involved in stress regulation, CBT-led stress reduction may be accompanied by a change in
pituitary volume. This study aimed to determine whether CBTp reduces pituitary volume in schizophrenia. The
relation between pre-therapy memory and CBTp-led pituitary volume change was also examined given that
poormemory relates to a blunted cortisol awakening response, denoting impaired stress response, in schizophre-
nia. Pituitary volume was measured at baseline in 40 schizophrenia or schizoaffective disorder patients and 30
healthy participants before therapy. Pituitary volume was measured again 6–9 months after patients had either
received CBTp in addition to standard care (CBTp+ SC, n=24), or continued with standard care alone (SC, n=
16). CBTp+ SC and SC groups were compared on pituitary volume change from baseline to follow-up. Pre-ther-
apy memory performance (Hopkins Verbal Learning andWechsler Memory Scale – Logical memory) was corre-
lated with baseline-to-follow-up pituitary volume change. Pituitary volume reduced over time in CBTp + SC
patients. Additionally, pre-therapy verbal learning correlated more strongly with longitudinal pituitary volume
reduction in the CBTp+ SC group than the SC group. To conclude, CBTp reduces pituitary volume in schizophre-
nia most likely by enhancing stress regulation and lowering the distress due to psychotic symptoms.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
The pituitary plays a key role in physiological stress regulation.
Stress stimulates the hypothalamic-pituitary-adrenal (HPA) axis to re-
lease corticosteroids from the hypothalamus and anterior pituitary
(Appiah-Kusi et al., 2015). In turn, the hypothalamus and anterior pitu-
itary stimulate cortisol release from the adrenal glands that lowers
stress reactivity. Through a negative feedback loop, high plasma cortisol
lowers hypothalamus and pituitary activity. The neural diathesis-stress
model of schizophrenia posits that a genetic predisposition to schizo-
phrenia combines with an accumulation of environmental factors, in-
cluding psychosocial stress, that disturb the homeostasis of the HPA
axis (Pruessner et al., 2017;Walker et al., 2008). This disturbance results
inHPA axis hyperactivity and elevated cortisol level that affect glucocor-
ticoid receptors in the hippocampus and medial prefrontal cortex, and
increases dopamine release and prominent psychotic symptoms.
Stress regulation is implicated in cognitive behavioural therapy for
psychosis (CBTp), because CBTp reduces distress due to psychotic expe-
riences (National Institute of Health and Clinical Excellence, 2014, NICE
Clinical Guideline 178). CBTp helps patients to modify their thoughts,
become aware of their reactivity to stressful situations, and think less
threateningly about psychotic experiences (National Institute of
Health and Clinical Excellence, 2014). CBT changes appraisal of psycho-
social stress and lowers cortisol levels in patients with generalized anx-
iety disorder by helping patients to generate strategies to overcome
anxiety (Rosnick et al., 2016). Poorer parental bonding at childhood re-
lates to lower cortisol awakening response in patientswithﬁrst-episode
psychosis (Pruessner et al., 2013). Certain acute psychosocial stressors
(e.g. performing cognitive tasks) result in sustained cortisol elevation
in schizophrenia (Nugent et al., 2015), while other social stressors
(e.g. public-speaking and job interviews) decrease cortisol levels
(Bradley and Dinan, 2010; Ciufolini et al., 2014). Consequently, in-
creased emotional reactivity to daily life stressors relates to larger pitu-
itary volume in patients with psychosis (Habets et al., 2012). However,
lower pre-CBT urinary cortisol relates to CBT-led reduction in symptom
severity in people with depression (Thase et al., 1996).
Schizophrenia Research xxx (2017) xxx–xxx
⁎ Corresponding author at: Department of Psychology, Nottingham Trent University,
Burton Street, Nottingham NG1 4BU, UK.
E-mail address: Preethi.premkumar@ntu.ac.uk (P. Premkumar).
SCHRES-07275; No of Pages 7
http://dx.doi.org/10.1016/j.schres.2017.04.035
0920-9964/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schres
Please cite this article as: Premkumar, P., et al., Pituitary volume reduction in schizophrenia following cognitive behavioural therapy, Schizophr.
Res. (2017), http://dx.doi.org/10.1016/j.schres.2017.04.035
Pituitary volume is reﬂective of HPA axis structure and function,
stress and psychosis severity. Greater perceived distress from adverse
life events relates to smaller pituitary volume in people who have a
ﬁrst or second degree relative with schizophrenia (Cullen et al., 2015).
Greater pituitary volume relates to higher plasma cortisol level three
years later in healthy adolescent boys (Kaess et al., 2013). Also, greater
pituitary volume relates to higher nocturnal cortisol in patients with de-
pression or bipolar disorder (Axelson et al., 1992). In schizophrenia, the
pituitary enlarges at the prodromal and early stages; then, it atrophies
over the chronic stage (Shah et al., 2015; Atmaca, 2014). Moreover, pi-
tuitary enlargement relates to less improvement of psychotic symptoms
in early psychosis (Garner et al., 2009; Takahashi et al., 2011). Nonethe-
less, evidence for the relation between pituitary volume and HPA axis
function in schizophrenia is scarce and contradictory.
1.1. The role of memory in HPA axis activity and CBTp responsiveness
Memory may be associated with stress regulation and HPA axis
function. Cortisol is a glucocorticoid, which binds to glucocorticoid re-
ceptors in the hippocampus and prefrontal cortex where memory is
formed and stored (Wingenfeld and Wolf, 2011). Cortisol binding to
glucocorticoid receptors in the hippocampus lowers HPA axis activity
(Jacobson and Sapolsky, 1991). Excessive endogenous and exogenous
cortisol impairs memory in healthy people (Wingenfeld and Wolf,
2011). In patients with ﬁrst-episode psychosis and children at risk for
psychosis, blunted cortisol awakening response (denoting the physio-
logical arousal due to the sleep-wake transition) relates to poorermem-
ory (Aas et al., 2011; Cullen et al., 2014). Perhaps, poor HPA axis
function can damage the hippocampus and diminish memory
(Karanikas and Garyfallos, 2015; Wingenfeld and Wolf, 2011). To our
knowledge, no study has investigated the association betweenmemory
and pituitary volume in schizophrenia patients. There is, however, evi-
dence of positive associations between pre-therapy verbal memory
and CBTp response (Penades et al., 2010), and larger hippocampal vol-
ume and CBTp response (Premkumar et al., 2009). Larger hippocampal
volume is consistently associated with better verbal memory in schizo-
phrenia (Antonova et al., 2004).
The aims of the present study were to determine whether CBTp re-
duces pituitary volume, and whether pre-therapy memory relates to
CBTp-led pituitary volume reduction. Firstly, it was hypothesized that
CBTp would reduce pituitary volume, because CBT helps patients to
ﬁnd stress regulation strategies and CBT reduces cortisol level
(Rosnick et al., 2016). Secondly, it was hypothesized that better pre-
therapy memory would relate to greater pituitary volume reduction in
patients receiving CBTp, because good memory in patients receiving
CBTp could lower stress-related cortisol level.
2. Methods and materials
2.1. Participants and design
Participants were 40 patients with a DSM-IV non-affective psychosis
diagnosis (First et al., 2002) recruited from the South London and
Maudsley NHS Foundation Trust; 24 patients received CBTp plus stan-
dard care (CBTp + SC), and 16 patients received standard care only
(SC). Thirty healthy participants matched on age, sex and number of
years in education, who reported no mental disorder history, were re-
cruited from the same geographical area as the patients. Participants
in this study have previously been examined for the neural effects of
CBTp (Kumari et al., 2011). Patient inclusion criteria were: (1) a DSM-
IVdiagnosis of schizophrenia or schizoaffective disorder, (2)willingness
to receive CBTp, (3) a stable dose of antipsychotic drugs for at least two
years and their current antipsychotic drug for at least three months, (4)
a score above 60 on the Positive and Negative Syndrome Scale (PANSS)
(Kay et al., 1987), and (5) having at least one distressing positive symp-
tom, i.e. scoring three or more on a PANSS positive item. In addition,
CBTp + SC patients were those who were referred to and accepted for
CBTp by the Psychological Interventions Clinic for Outpatients with Psy-
chosis (PICuP) at the South London and Maudsley NHS Foundation
Trust. By following opportunistic sampling, the psychiatrists in the par-
ticipating psychiatric services recommended suitable patients to be al-
located to the SC group. The Joint South London and Maudsley and the
Institute of Psychiatry Research Ethics Committee approved the study.
All participants provided written informed consent.
CBTp aims to reduce distress, depression, anxiety and hopelessness
by minimizing interference arising from psychotic symptoms (Fowler
et al., 1995). Therapy was delivered weekly or fortnightly (as preferred
by the patient) over an average of 16 individual one-hour sessions for 6–
9 months. In initial sessions, the therapist engaged the patient by
forming a therapeutic relationship and focusing on the patient's needs.
Standard care consisted of typical and atypical antipsychoticmedication
and six-monthly care plan assessment reviews delivered by a caseman-
agement team, with a view to recovery. The casemanagement team in-
cluded a dedicated care coordinator who saw the patient at regular
intervals, a psychiatrist and other specialists, such as a clinical psychol-
ogist and occupational therapist.
2.2. Clinical and memory assessments
Experienced psychiatrists (DF and APA) diagnosed the patients
using the Structured Clinical Interview for DSM-IV (First et al., 2002),
blind to the type of intervention patients received (CBTp + SC or SC).
The psychiatrists assessed patients' symptom severity using the PANSS
(Kay et al., 1987) before and after CBTp, or 6–9 months after baseline
in the SC group. Trained doctoral-level researchers assessed partici-
pants' pre-therapymemory blind to the hypotheses being tested. Partic-
ipants were assessed on Wechsler Memory Scale – III Logical Memory
(WMS-LM, Wechsler, 1998) and Hopkins verbal learning test (HVLT,
Shapiro et al., 1999). In WMS-LM, participants listened to two stories
read by the examiner and recalled the stories immediately (immediate
recall) and then, half an hour later (delayed recall). Immediate and de-
layed recall scores were calculated by scaling the raw scores to the age-
related norms of the test. In HVLT, participants listened to a list of 12
words read out by the researcher three times. Participants recalled the
list each time. Verbal learning was calculated as the total number of
freely recalled items across the three trials.
2.3. Pituitary and whole brain volumetry
T1-weighted structural magnetic resonance imaging brain scans
were acquired in the axial plane with 1.5 mm contiguous slices from a
1.5 Tesla NV/i Signa scanner (General Electric, Milwaukee, Wisconsin)
at the Centre for Neuroimaging Sciences, King's College London (TR
= 18ms, TI = 450ms, TE= 5.1 ms, ﬂip angle = 20° with one data av-
erage and a 256 × 256 × 128 voxel matrix). Patients were scanned at
baseline and follow-up, while healthy participants were scanned at
baseline only. Volumetry was performed manually using the MEASURE
programme based on the Cavalieri principle (Barta et al., 1997). The
Cavalieri principle states that the volume of an object may be estimated
by sectioning it with a set of uniformly spaced parallel planes and mea-
suring the cross-sectional area of the object on each plane (Barta et al.,
1997). Trained researchers measured the pituitary (DB, AS and PPK)
and whole brain volume (PPK) blind to group membership and treat-
ment allocation. Novice raters achieved 95% accuracy against a trained
rater's measurement of the region of interest on ten test brain scans be-
fore beginning to measure the study participants' brain scans. The pitu-
itary was deﬁned as a hyper-intensity adjacent to the posterior pons on
the sagittal view, with clearly deﬁned anterior and posterior boundaries
(Klompet al., 2012; Tien et al., 1992). The infundibular stalkwas exclud-
ed from the segment (Fig. 1). Thewhole brain included the cerebral cor-
tex, namely frontal, temporal, parietal and occipital lobes, and the sub-
cortex, namely the basal ganglia and thalamus (DeLisi et al., 1995).
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The cerebellum, brain stem, ventricles and cerebrospinal ﬂuid were not
included in whole brain volume measurement.
2.4. Statistical analysis
Demographic characteristics (age, sex and years in education) were
compared between groups using analysis of variance (ANOVA) or Chi-
square test. Illness duration (deﬁned as number of years since ﬁrst hos-
pitalization), change in PANSS symptom severity and change in antipsy-
chotic dosage from baseline to follow-up were compared between
patient groups. Improvement in stress-related items in the CBTp
group, namely depression, excitement and anxiety, was tested using
non-parametric tests (no signiﬁcant symptom change in the SC group;
see Results). Prolactin-enhancing drugs (all typical antipsychotics, and
risperidone and amisulpride) stimulate prolactin-secreting cell prolifer-
ation, and consequently anterior pituitary enlargement (MacMaster et
al., 2007; Pariante, 2008). Thus, the number of patients receiving each
antipsychotic drug type, i.e. prolactin-enhancing and prolactin-sparing
(all other atypical antipsychotics), was compared between patient
groups. Pre-therapy memory, WMS-LMmemory and HVLT scores, was
compared between groups, with group (CBTp + SC, SC and healthy)
as independent variable, and number of years in education and age as
a covariates.
Pituitary volume at baseline was compared between CBTp + SC, SC
and healthy groups using analysis of covariance, with age and whole
brain volume as covariates. The longitudinal change in pituitary volume
was compared between patient groups, with sex as an additional be-
tween-participants factor, and illness duration andwhole brain volume
at baseline as covariates.We included sex as a between-participants fac-
tor, because pituitary volume is larger in healthy women thanmen and
in men than women with schizophrenia (Romo-Nava et al., 2013;
Upadhyaya et al., 2007).
One-tailed correlationswere performed to test associations between
baseline-to-follow-up pituitary volume change and pre-therapymemo-
ry (scores on the HVLT and WMS-LM), because the directional
hypothesis stated that better pre-therapy memory would relate to
greater post-CBTp pituitary volume reduction. If a correlation was sig-
niﬁcant, a partial correlation was performed, with illness duration,
whole brain volume and number of years in education as covariates.
Statistical analyses were performed in Statistical Package for Social Sci-
ences (Version 22), with p b 0.05 as the signiﬁcance level.
3. Results
3.1. Demographic characteristics and symptom reduction following CBTp
Healthy participants were older than patients (Table 1). Speciﬁcally,
healthy participants were older than SC patients (p=0.04). Groups did
not differ in sex, years in education, illness duration, or antipsychotic
drug type at baseline or follow-up. The CBTp+ SC group comprised pa-
tients with paranoid schizophrenia (79%), schizoaffective disorder
(12%) and schizophrenia not otherwise speciﬁc (8%). The SC group com-
prisedpatientswith paranoid schizophrenia (81%), residual schizophre-
nia (12%) and schizoaffective disorder (6%). From baseline to follow-up,
CBTp+ SC patients improved in positive symptoms, F (1,23)=15.9, p b
0.01, negative symptoms, F(1,23) = 5.9, p= 0.02, and general psycho-
pathology, F(1,23) = 8.6, p = 0.01. The SC group did not show any
symptom change (p N 0.1). Besides, negative symptoms and overall
symptoms improved more in the CBTp + SC than SC group (Table 1).
When improvement in stress-related items in the CBTp group, namely
depression, excitement and anxiety, was tested, depression and excite-
ment improved signiﬁcantly, z(23)=1.96, p=0.05 and z(23)=2.29, p
= 0.03, respectively. Improvement in anxiety approached signiﬁcance,
z(23) = 1.75, p= 0.08. Pre- to post-therapy antipsychotic dosage de-
creased in the CBTp + SC group, but increased in the SC group.
The healthy group did not differ in WMS-LM immediate recall from
the CBTp+ SC group, mean difference = 1.4 ± 0.8, p= 0.29, or the SC
group,meandifference=2.3±1.0, p=0.06. The healthy groupdid not
differ in WMS-LM delayed recall from the CBTp + SC group, mean dif-
ference = 1.5 ± 0.7, p= 0.1, but had better delayed recall than the SC
Fig. 1. Pituitary rating (highlighted in red) as seen from the (a) sagittal, (b) coronal, and (c) axial views taken from amid-sagittal slice. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
3P. Premkumar et al. / Schizophrenia Research xxx (2017) xxx–xxx
Please cite this article as: Premkumar, P., et al., Pituitary volume reduction in schizophrenia following cognitive behavioural therapy, Schizophr.
Res. (2017), http://dx.doi.org/10.1016/j.schres.2017.04.035
group, mean difference= 2.8 ± 0.8, p=0.05. Healthy participants had
better verbal learning (HVLT free recall) than the CBTp + SC group,
mean difference = 5.0 ± 1.4, p= 0.003, but did not differ from the SC
group, mean difference = 3.3 ± 1.7, p = 0.2. The CBTp + SC and SC
groups did not differ in either WMS-LM immediate recall, mean differ-
ence = 0.9 ± 1.0, p = 1.0, WMS-LM delayed recall, mean difference
= 0.6 ± 0.8, p = 1.0, or HVLT free recall, mean difference =−1.7 ±
1.7, p= 1.0.
3.2. Pituitary volume change from baseline to follow-up: differences be-
tween CBTp + SC and SC groups
CBTp+ SC, SC and healthy groups did not differ in baseline pituitary
volume (Table 2). The group-by-time interaction approached statistical
signiﬁcance, F(1,34)=3.56, p=0.07. Post hoc analyses compared pitu-
itary volume at baseline and follow-up in each group individually while
controlling for illness duration. The analyses showed an effect of time in
the CBTp + SC group, F(1,22) = 4.54, p = 0.04, but not the SC group,
F(1,14)= 2.97, p=0.11. Antipsychotic drug type (prolactin-enhancing
or prolactin-sparing) did not have an effect on pituitary volume change,
i.e., the patient group-by-drug type-by-time interaction was not signif-
icant (Table 2). The main effect of time was non-signiﬁcant, F(1,34) =
0.01, p= 0.93.
3.3. Association between pituitary volume change and pre-therapymemory
in CBTp + SC patients
In the CBTp + SC group, verbal learning at baseline was associated
with pituitary volume reduction during the treatment phase (Table 3).
The correlationwas still signiﬁcant in the CBTp+SC group after covary-
ing for illness duration, whole brain volume and years in education, r=
−0.64, p=0.001, but not the SC group, r=−0.06, p=0.419. Also, the
correlation was stronger in the CBTp + SC group than the SC group as
per Fisher's r-to-z transformation, z = 1.99, p= 0.02 (Fig. 2).
4. Discussion
The study aimed to examine whether pituitary volume decreases
following CBTp in schizophrenia patients, as pituitary volume is a po-
tentialmarker of HPA axis function.We hypothesized that pituitary vol-
ume would decrease, because CBT-led stress reduction lowers cortisol
levels (Rosnick et al., 2016) and lower cortisol relates to lower pituitary
volume (Axelson et al., 1992). As hypothesized, pituitary volume de-
creased over time in the CBTp + SC group relative to the SC group.
We also hypothesized that better pre-therapy memory would relate to
CBTp-led pituitary volume reduction. Better pre-therapymemory relat-
ed to CBTp-led pituitary volume reduction, such that the association
was stronger in the CBTp + SC group than the SC control group.
Table 1
Demographic and clinical characteristics of patients receiving CBTp + SC (n= 24), SC (n= 16) and healthy participants (n= 30).
Characteristic CBTp + SC SC Healthy Model F or Chi2 (df) p Value
Sex: men/women (n) 17/7 13/3 20/10 Group × sex 1.09 (2) 0.58
Age (in years) 36.1 ± 8.48 42.1 ± 9.6 34.2 ± 11.3 Group 3.3 (2,67) 0.04
Years in education 14.1 ± 3.1 13.3 ± 1.4 14.9 ± 2.1 Group 2.5 (2,67) 0.09
Duration of illness (in years) 11.4 ± 7.8 15.6 ± 12.1 Group 1.8 (1,38) 0.18
Baseline Follow-up Baseline Follow-up
Prolactin-enhancing/prolactin-sparing
antipsychotics at baseline (n)
7/17 5/19 5/11 6/10 Group × drug type
at baseline
0.02 (1) 0.89
Group × drug type
at follow-up
1.3 (1) 0.25
Positive 17.8 ± 3.5 14.9 ± 3.9a 18.5 ± 3.7 17.1 ± 3.5 – Group × time 1.8 (1,38) 0.18
Negative 17.4 ± 3.5 15.6 ± 4.0a 18.9 ± 3.7 19.9 ± 5.0 – Group × time 4.8 (1,38) 0.03
General psychopathology 32.5 ± 5.0 28.5 ± 6.8a 34.9 ± 4.3 33.9 ± 7.4 – Group × time 1.9 (1,38) 0.17
Antipsychotic dosage (CPZ equivalent) 517.3 ± 386.2 480.3 ± 385.7 503.7 ± 329.8 627.9 ± 612.5 Group × time 4.9 (1,38) 0.03
Pre-therapy memory Group 3.2 (3,130) 0.01
WMS-LM – immediate recall 7.5 ± 2.6 6.1 ± 3.3 9.1 ± 3.0 Group 3.1 (2,65) 0.05
WMS-LM – delayed recall 8.2 ± 2.2 7.3 ± 2.5 10.0 ± 2.8 Group 3.9 (2,65) 0.03
HVLT total free recall 20.4 ± 6.4 20.9 ± 5.5 26.1 ± 4.4 Group 6.1 (2,65) 0.004
CBTp: Cognitive behavioural therapy for psychosis, CPZ: chlorpromazine, HVLT: Hopkins verbal learning test; PANSS: Positive and Negative Syndrome Scale, SC: standard care, WMS-LM:
Wechsler Memory Scale – III Logical Memory test.
a CBTp-led symptom improvement.
Table 2
Pituitary volume at baseline inhealthyparticipants (n=30), patients receiving CBTp (n=24) and patients receiving standard care (n=16), and at follow-up inpatients receiving CBTpor
standard care based on antipsychotic drug type.
Characteristic CBTp + SC SC Healthy Model F (df) p Value
Baseline Follow-up Baseline Follow-up
Pituitary volume (mm3) 473.4 ± 75.9 409.1 ± 108.4 481.6 ± 132.0 445.0 ± 127.3 510.7 ± 147.9 Group difference at baseline 0.5 (2,65) 0.62
Group × time 3.5 (1,34) 0.07
Patients receiving prolactin-enhancing antipsychotic drugs Group × drug type × time 0.4 (1,34) 0.5
N= 7 N= 5
513.8 ± 77.9 438.2 ± 92.8 414.1 ± 85.7 392.3 ± 74.7
Patients receiving prolactin-sparing antipsychotic drugs
N= 17 N= 11
456.8 ± 70.8 397.1 ± 114.6 512.3 ± 41.0 469.0 ± 141.6
CBTp: Cognitive behavioural therapy for psychosis, SC: standard care.
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4.1. CBTp-led pituitary volume reduction
Our study is the ﬁrst to report on the effect of CBT on pituitary vol-
ume in any disorder. Pituitary volume reduced after therapy in the
CBTp + SC group. Further, the stress-related symptoms (depression
and excitement) in the CBTp + SC group improved after therapy. High
stress-induced plasma cortisol relates to greater severity of psychotic
and negative symptoms (Tandon et al., 1991; Walder et al., 2000),
whereas CBT lowers cortisol level (Rosnick et al., 2016). Thus, lower
stress may reduce pituitary volume in chronic psychosis. This explana-
tion is plausible because lower stress reactivity and lower cortisol
level relate to smaller pituitary volume in patients with psychosis or bi-
polar disorder (Axelson et al., 1992; Habets et al., 2012). Effective stress-
regulation strategies lower endogenous cortisol by improving HPA axis
regulation (Abelson et al., 2014). Certain CBT stress regulation strategies
may engage the HPA axis better than others. Externalizing one's stress
(e.g. wanting to do good for others) decreases cortisol level more than
internalizing one's stress (e.g. reducing one's appraisal of social threat)
when exposed to psychosocial stress, such as a job interview (Abelson
et al., 2014). CBTp may help patients to think ﬂexibly about their psy-
chotic experiences and perceive less social stress (Garety et al., 1997;
Mason et al., 2016).
4.2. Relation between better pre-therapy memory and greater CBTp-led pi-
tuitary volume reduction
We found that better pre-therapy memory, speciﬁcally verbal
learning, related to CBTp-led pituitary volume reduction. Greater
pre-therapy verbal learning could relate to greater post-therapy
pituitary volume reduction because memory activates the hippo-
campus. Memory-led hippocampal activation inhibits HPA axis
activity (Naughton et al., 2014; Phillips et al., 2006). Furthermore,
cortisol binds to glucocorticoid receptors that are abundant in hippo-
campus and prefrontal cortex. Cortisol binding to the hippocampus
and pituitary inhibits HPA axis function (Jacobson and Sapolsky,
1991). In patients with ﬁrst-episode psychosis and children at risk
for psychosis, poor HPA axis function due to blunted cortisol awak-
ening response relates to poorer memory (Aas et al., 2011; Cullen
et al., 2014). Preserved memory and cognitive ﬂexibility may en-
hance CBTp responsiveness in schizophrenia (Penades et al., 2010;
Garety et al., 1997). Previously, we failed to ﬁnd an association be-
tween pre-therapy memory and CBTp responsiveness in the CBTp
+ SC patients who participated in the current study (Premkumar
et al., 2011). In that study however, pre-therapy memory was exam-
ined in relation to the change in composite subscale scores, rather
than change in stress-related items. Also, atypical anti-psychotics
may reduce elevated cortisol (Cohrs et al., 2006), and CBTp could en-
hance adherence to the treatment. Thus, lower stress may promote
cortisol binding to the hippocampus and prefrontal cortex, and im-
prove HPA axis negative feedback loop function.
The study has limitations. Firstly, pituitary volume was not mea-
sured in healthy participants at follow-up. Thus, it is not possible to
rule out the effect of time and other non-speciﬁc effects on pituitary vol-
ume reduction. Prolactin-sparing antipsychotic drugs reduce pituitary
volume more than prolactin-enhancing antipsychotic drugs in chronic
schizophrenia (Klomp et al., 2012; Takahashi et al., 2012). However,
drug type did not explain pituitary volume reduction in the current
study. Furthermore, we included patients who were on stable antipsy-
chotics for two years and receiving the current antipsychotic for six
months. Thus, any antipsychotic medication-induced pituitary change
would have been present before CBTp. Secondly, patients had normal
pre-therapy pituitary volume. Normal pituitary volume in chronic
schizophrenia is a consistent ﬁnding (Tournikioti et al., 2007). The ap-
parent ‘normal’ pituitary volume in patients may be confounded by
stress-related enlargement due to prolactin-secreting cell proliferation
caused by prolactin-enhancing antipsychotics (Pariante, 2008). Thirdly,
the small sample size of the participant groups could have increased the
likelihood of a Type II error. Lastly, the lack of data on cortisol level to
test HPA axis function makes it difﬁcult to verify the functional signiﬁ-
cance of pituitary volume reduction.
In conclusion, CBTp-led symptom improvement may longitudinally
lead to pituitary volume reduction. Better verbal learning may enhance
recall of CBTp stress-regulation techniques, which is a potential mecha-
nism by which pituitary volume reduction occurs.
Table 3
Correlation, r (p-value), between pre-therapymemory and pituitary volume change from
baseline to follow-up in the CBTp + SC (n= 24) and SC control (n= 16) groups.
Pituitary volume
CBTp + SC SC control
HVLT – free recall −0.6 (0.001) −0.1 (0.4)
WMS-LM immediate recall −0.1 (0.32) 0.1 (0.33)
WMS-LM delayed recall −0.1 (0.31) −0.05 (0.42)
Values in bold are statistically signiﬁcant.
Fig. 2. Scatterplot of pituitary volume change from baseline to follow-up against Hopkins verbal learning test score at baseline in CBTp + SC and SC patients.
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